A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 1
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
Cited by
Items 501–600 of 649
Gene fusion of IL7 involved in the regulation of idiopathic pulmonary fibrosis
Sun, S., Huang, C., Leng, D., Chen, C., Zhang, T., Lei, K. C., & Zhang, X. D. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466621995045 · Cited by 4
Time to share: lessons from post hoc analyses of IPF trials
Kass, D. J., & Kaminski, N. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-209293 · Cited by 4
Progress through Persistence — Turning the Page in Pulmonary Fibrosis Clinical Trials
Lee, J. S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505760 · Cited by 4
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Immunological mechanisms and therapeutic approaches in pulmonary fibrosis
Nell, L. M., Hendriks, R. W., Wijsenbeek, M. S., Corneth, O. B. J., & Koudstaal, T. (2026) · European Respiratory Review · doi:10.1183/16000617.0227-2025 · Cited by 5
Therapie der idiopathischen interstitiellen Pneumonien
Prasse, A., & Müller–Quernheim, J. (2006) · Der Internist · doi:10.1007/s00108-006-1734-4 · Cited by 3
“Konsens besteht darin, dass die genannte Kombinationstherapie keinen ausreichenden Therapieansatz der IPF darstellt und dass dringend weitere Therapieoptionen entwickelt werden müssen [11].”
BackgroundExacerbaciones agudas de la fibrosis pulmonar idiopática
Vázquez, J. M. V., Dobaño, J. M. Á., González‐Barcala, F. J., & Valdés, L. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2009.12.015 · Cited by 3
Yin Yang-1(YY-1) expression in idiopathic pulmonary fibrosis
Margaritopoulos, G., Antoniou, K. M., Soufla, G., Vassalou, E., Spandidos, D. A., & Siafakas, N. M. (2011) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2011.557735 · Cited by 3
Chung, M. P. (2006) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2006.61.4.321 · Cited by 3
Development of Adaptive Immunity and Its Role in Lung Remodeling
Esnault, S. J., & Jarjour, N. N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-32259-4_14 · Cited by 4
« Classification 2002 des pneumopathies interstitielles idiopathiques »
Boniface, S., Gaubert, J., Chetaille, B., Fraticelli, A., Rétornaz, F., Astoul, P. J., VERVLOET, D., Magnan, A., & Reynaud‐Gaubert, M. (2004) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2004.07.020 · Cited by 3
Treatment of Idiopathic Pulmonary Fibrosis: A European Perspective
Hoyles, R. K., & du Bois, R. M. (2006) · Clinical Pulmonary Medicine · doi:10.1097/01.cpm.0000198144.90287.1f · Cited by 3
Novel therapy for idiopathic pulmonary fibrosis—How to evaluate the efficacy?
Azuma, A., & Usuki, J. (2008) · Respiratory Medicine CME · doi:10.1016/j.rmedc.2008.06.001 · Cited by 3
Les antagonistes des récepteurs de l’endothéline : leur place dans les maladies pulmonaires
Boniface, S., & Reynaud‐Gaubert, M. (2009) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(09)73534-x · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Drug-Induced Respiratory Disease in Connective Tissue Diseases
Camus, P. (2004) · Technical report · doi:10.1016/s1571-5078(04)02013-6 · Cited by 4
Hypocapnia in Acute Pulmonary Edema
Masip, J., Páez, J., Sánchez, B., & Cancio, B. (2004) · Respiration · doi:10.1159/000081773 · Cited by 3
Poor Choice of Primary Outcome in a Clinical Trial of Pirfenidone in Patients with IPF
Levitt, J. E., & Gould, M. K. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.172.9.951 · Cited by 3
Jenkins, G. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206209 · Cited by 3
Interferon-γ 1b in Idiopathic Pulmonary Fibrosis
Dauber, J. H., Gibson, K. F., & Kaminski, N. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2405001 · Cited by 3
“Nonetheless, the results provide a mechanistic mirror to the clinical study by Raghu and coworkers ( 4 ).”
BackgroundResultInfluentialTargeted treatment of idiopathic pulmonary fibrosis: one step at a time
Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00389-2016 · Cited by 3
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Wongkarnjana, A., & Ryerson, C. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00894-2020 · Cited by 3
Nyaupane, U., Johannson, K. A., Kelly, M. M., & Kai, F. (2025) · Experimental Lung Research · doi:10.1080/01902148.2025.2582970 · Cited by 1
“15,16 Consequently, inflammatory pathways have generally been viewed as poor therapeutic targets in IPF.”
Prevalence, Detection, and Trajectory of Combined Pulmonary Fibrosis and Emphysema
Khor, Y. H., Marinescu, D.-C., Manganas, H., Morisset, J., Müller, N. L., Hague, C. J., Murphy, D., Churg, A., Wright, J. L., Al-Arnawoot, A., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.05.051 · Cited by 2
Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis
Fabre, T., Wynn, T. A., & Hart, K. M. (2026) · Nature Immunology · doi:10.1038/s41590-026-02616-1 · Cited by 2
“Recombinant IFNγ was tested as an anti-fibrotic treatment in IPF, but it failed to improve fibrosis and was poorly tolerated owing to peripheral inflammation 78,79 .”
Phase three clinical trials in idiopathic pulmonary fibrosis
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1882299 · Cited by 2
“gov Identifier NCT00047645) did not meet either the primary outcome (progression-free survival, defined as either disease progression or death) or any of the secondary ones, including functional measurements, gas exchange values and QoL tools [31].”
BackgroundSingh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
Varney, V. (2012) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000127 · Cited by 3
Interstitial Lung Disease and Lung Transplantation
Berastegui, C., Román, A., & Morell, F. (2011) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e31823510af · Cited by 2
Traitement des pneumopathies interstitielles diffuses
Cottin, V. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)71669-2 · Cited by 2
Le traitement des fibroses pulmonaires idiopathiques
Dury, S. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)71556-x · Cited by 2
Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis
Miura, Y., & Azuma, A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1029453 · Cited by 2
“As IFN-g replacement therapy showed no efficacy in IPF [14,15], simple blocking or complementary therapy may not be effective for IPF.”
BackgroundMethodRaghu, G. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00067306 · Cited by 2
Self-citationNew approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Cerri, S., Giovane, C. D., Balduzzi, S., Soncini, F., Sdanganelli, A., & Richeldi, L. (2013) · Clinical Investigation · doi:10.4155/cli.13.39 · Cited by 2
Diffuse Lung Disease: Classification and Evaluation
Collard, H. R., & King, T. E. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_6 · Cited by 2
Self-citationCurrent and Future Therapies for Idiopathic Pulmonary Fibrosis
Maher, T. M. (2011) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3182350bb4 · Cited by 2
Differenzielle Therapie bei Lungenfibrosen
Markart, P., Seeger, W., & Günther, A. (2006) · Der Internist · doi:10.1007/s00108-006-1641-8 · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
“Against expectations, the two Phase 3, randomized, double-blind, placebo-controlled trials of interferon γ-1b in IPF (GIPF-001 [NCT00047645] and GIPF-007 [NCT00075998]) had not found a treatment effect on progression-free survival, pulmonary function, quality of life, or mortality in IPF patients and lung transplantat…”
BackgroundIdiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Mohning, M. P., Swigris, J. J., & Olson, A. L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_2 · Cited by 2
Aronson, K. I., Jacobs, S. S., Repola, D., & Swigris, J. J. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001546 · Cited by 2
Acetylcysteine in Pulmonary Fibrosis
Hull, J. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053493 · Cited by 2
Health effects of quercetin : from mechanism to nutraceutical
Boots, A. W. (2006) · Research Publications (Maastricht University) · doi:10.26481/dis.20061221ab · Cited by 6
Wells, A. U., Richards, T. J., & Martínez, F. J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201107-1216ed · Cited by 2
Pneumopathies interstitielles diffuses idiopathiques
Bergeron, A., Tazi, A., & Crestani, B. (2004) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(04)71598-3 · Cited by 2
External validity of randomised controlled trials in idiopathic pulmonary fibrosis
Thomeer, M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00151305 · Cited by 2
Nuevos tratamientos en la fibrosis pulmonar idiopática
Montero-Martínez, C. (2006) · Archivos de Bronconeumología · doi:10.1157/13083273 · Cited by 2
Immunopathogenetic and Pharmacological Aspects of Interstitial Lung Diseases
Mazzoccoli, G., Cata, A. D., de Pinto, G. D., de Matthaeis, A., & Vendemiale, G. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300401 · Cited by 3
Adjuvant Interferon Gamma in the Management of Multidrug - Resistant Tuberculosis
Garca-Garca, I., Mara, T., Pedro, A., Surez-Mndez, R., Valdés-Quintana, M., Olivera, N. F., del Carmen, M., Gonzlez-, L., Herrera, Y. S., Suárez, G. A., et al. (2012) · InTech eBooks · doi:10.5772/29906 · Cited by 1
“Nevertheless, patients with an initial less deteriorate pulmonary function impairment showed better survival (Raghu et al., 2004).”
BackgroundCloning and high level expression of bovine interferon gamma gene in eukaryotic cells (COS-7)
Brujeni, G. N. (2010) · Majallah-i taḥqīqāt-i dāmpizishkī-i īrān · doi:10.22099/ijvr.2010.149 · Cited by 1
Perspectivas en el tratamiento de la fibrosis pulmonar idiopática
Morell, F., & Villar, A. (2012) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(12)70046-7 · Cited by 1
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Baroke, E., Maharaj, S. S., & Kolb, M. R. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.155 · Cited by 2
Idiopathic Pulmonary Fibrosis: New Concept of Pathogenesis and Treatment
Uh, S. (2009) · Journal of Korean Medical Association · doi:10.5124/jkma.2009.52.1.22 · Cited by 1
Sharma, O. P. (2004) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000130331.67540.f8 · Cited by 1
Recent advances in interstitial lung disease research
Vassallo, R. (2006) · OAR@UM (University of Malta) · Cited by 2
Radiographic Imaging in Interstitial Lung Disease and Pulmonary Hypertension
Carbone, R. G., Monselise, A., & Bottino, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_1 · Cited by 1
Traitement de la fibrose pulmonaire idiopathique
Valeyre, D., & Dion, G. (2010) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32328-3 · Cited by 1
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Self-citationSteinke, J. W., Illei, G. G., Uzel, G., & Mican, J. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10094-6 · Cited by 1
Wells, A. U., & Хирани, Н. (2009) · PULMONOLOGIYA · doi:10.18093/0869-0189-2009-4-11-57 · Cited by 2
Loeh, B., Korfei, M., Mahavadi, P., Wasnick, R. M., von der Beck, D., & Günther, A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004815 · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00902-1 · Cited by 1
La fibrose pulmonaire idiopathique
Uzunhan, Y. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70126-9 · Cited by 1
Meyer, K. C., & Raghu, G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-074-8_3 · Cited by 1
Self-citationPneumopathies interstitielles idiopathiques
Nunès, H. (2005) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(05)85678-5 · Cited by 1
Mortality, a Bar Too High for Idiopathic Pulmonary Fibrosis Clinical Trials!
Behr, J. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201205-0926le · Cited by 2
Pneumopathies interstitielles diffuses
Nunès, H. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)92793-x · Cited by 1
Fontenot, A. P., & Schwarz, M. I. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10071-5 · Cited by 1
Thoughts on the Diagnosis and Management of Interstitial Lung Diseases
de Andrade, J. A. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e31805f6da0 · Cited by 1
Mutations in Surfactant Protein C and Interstitial Lung Disease
Panos, R. J., & Bridges, J. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-59745-384-4_6 · Cited by 1
Voeghtly, L. (2009) · D-Scholarship@Pitt (University of Pittsburgh)
Orzechowski, K. (2008) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-17724
Plant, B. J., & Egan, J. J. (2005) · Wiley eBooks · doi:10.1002/9780470987377.ch36
Munar, M. A., Pantoja, J. A., Santacruz, J. C., Villate, A. M., Bastidas, A., & Giraldo‐Cadavid, L. F. (2012) · Revista Med · doi:10.18359/rmed.1203 · Cited by 1
“Posteriormente, 2 estudios clínicos —randomizados, controlados y con placebo— mostraron eficacia con esta intervención, sin embargo, no se logró mostrar ningún beneficio en los desenlaces primarios, ni secundarios (79).”
BackgroundCurrent and Emerging Treatment Options in Interstitial Lung Disease
Maher, T. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0770-0_14
Gelbman, B. D., & Crystal, R. G. (2006) · Elsevier eBooks · doi:10.1016/b978-012595961-2/50070-6
C6 Immunostimulants in cancer therapy
Talmadge, J. E. (2011) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0136-8_21
Vannella, K. M. (2009) · Deep Blue (University of Michigan)
Update on New Treatments for Idiopathic Pulmonary Fibrosis
DeGrado, J. R., & Gilmore, J. F. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0076-8
Eastwood, P. R., Takahashi, K., Lee, P., & Maher, T. M. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.01927.x
Extracellular Superoxide Dismutase and Matrix Metalloproteinases in Pulmonary Fibrosis
Tan, R. J. (2005) · D-Scholarship@Pitt (University of Pittsburgh)
Calidad de vida en pacientes con fibrosis pulmonar idiopática
Tabaj, G. C., Quadrelli, S., Grodnitzky, L., & Sinagra, P. (2012) · Redalyc (Universidad Autónoma del Estado de México)
Manejo general y extrahospitalario del paciente con enfermedad pulmonar intersticial
Gracia, F. D., & Ariño, A. S. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70198-0
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Spagnolo, P., & Luppi, F. (2013) · Clinical Investigation · doi:10.4155/cli.13.107
Le doute persiste concernant l’efficacité de l’interféron-gamma dans la fibrose pulmonaire
Crestani, B. (2004) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(04)72042-2
Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going
Luppi, F., Spagnolo, P., Cerri, S., Sgalla, G., & Richeldi, L. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-012-0030-0
“This study formed the basis for a large, multicenter, randomized, placebo-controlled trial in which 330 IPF patients (who had failed to respond to a course of corticosteroids) were randomized to subcutaneous IFNgamma or placebo [21].”
BackgroundMethodResultAcute Respiratory Failure After a Single Dose of Interferon-gamma
Singh, J., & Steele, M. P. (2004) · CHEST Journal · doi:10.1378/chest.126.4_meetingabstracts.994s-a
The line between scientific uncertainty and promotion of snake oil
Silverman, E. (2013) · BMJ · doi:10.1136/bmj.f5687
Le reflux gastro-œsophagien en pneumologie
Jouneau, S. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70123-3 · Cited by 1
La fibrose pulmonaire idiopathique
Uzunhan, Y. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72538-8
Sauty, A., & Aubert, J. (2005) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(05)72917-x
Lung transplantation: a therapy for interstitial lung disease?
Whelan, T. P. M. (2006) · Current Opinion in Organ Transplantation · doi:10.1097/01.mot.0000244649.93093.c0
Enfermedad pulmonar intersticial idiop?tica. Concepto. Etiopatogenia
Adell, I. S., Snchez, M. T. L., Campo, J. L. M. D., Lanza, A. M., & Pandiella, J. R. (2006) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(06)74395-8
Respiratory medicine: interstitial pneumonia, cystic fibrosis and pulmonary hypertension
Mulrennan, S. A., & Muers, M. F. (2006) · Medicine · doi:10.1053/j.mpmed.2006.10.001
Azetylzystein bei idiopathischer Lungenfibrose
Kirsten, D. K. (2006) · Der Pneumologe · doi:10.1007/s10405-006-0085-0
Vaquero, M. (2008) · Revista Española de Patología · doi:10.1016/s1699-8855(08)70103-x · Cited by 1
“En cuanto al tratamiento, en la revisión de ensayos clínicos randomizados (57-60) que utilizaron corticoides para el tratamiento de la FPI no se observó una eficacia significativa, por lo que se sugiere intentarlo con sustancias inmunomoduladoras.”
BackgroundTreatment of idiopathic interstitial pneumonias
Corte, T. J., & Wells, A. U. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.3.1.81
Pneumonias intersticiais idiopáticas – Uma revisão da literatura
Mota, P. J. D. L. (2006) · Revista Portuguesa de Pneumologia · doi:10.1016/s0873-2159(15)30454-2 · Cited by 2
Clinical networks for ILD: casting light on diffuse lung shadows
Harrison, N., Johnson, N. M., & WILSHER, M. L. (2010) · Thorax · doi:10.1136/thx.2009.122135
“Patients requesting a second opinion or seeking the opportunity to enter a clinical trial.”
BackgroundRossi, G. P., & Agostini, C. (2009)
INTERSTITIAL LUNG DISEASE | Idiopathic Pulmonary Fibrosis
Martínez, F. J., Hogaboam, C. M., Choi, E. S., Toews, G. B., Flaherty, K. R., & Thannickal, V. J. (2006) · Elsevier eBooks · doi:10.1016/b0-12-370879-6/00197-6
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.